Nautilus Biotechnology (NAUT) Non Operating Investment Income (2020 - 2021)

Nautilus Biotechnology (NAUT) reported Non Operating Investment Income of $10982.0 for Q1 2021, down 79.26% sequentially from $52952.0 in Q4 2020.

Nautilus Biotechnology (NAUT) Non Operating Investment Income (2020 - 2021) Analysis & Trends

Nautilus Biotechnology (NAUT) has 2 years of Non Operating Investment Income data on file, last reported at $10982.0 in Q1 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non Operating Investment Income (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-	-
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn	-
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn	-
7	Belite Bio	62.72 Bn	62.72 Bn	-	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn	-
9	Revolution Medicines	37.35 Bn	37.35 Bn	-	-
10	Nautilus Biotechnology	212.11 Mn	116.24 Mn	-	-

Download Data